10X Genomics

10X Genomics Current Liabilities

The Current Liabilities of 10X Genomics (TXG) as of Oct 22, 2026 is 223.01 M USD. In the previous year, Current Liabilities was 154.04 M USD — a change of 44.77% (higher).

Current Liabilities

223.01 MUSD

YoY

44.77%

Last updated:

Current Liabilities of 10X Genomics is 2025 223.01 M USD. Current Liabilities of 10X Genomics was 2024 154.04 M USD. It decreases by 44.77% higher compared to the previous year.

The 10X Genomics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
45.53 M USD
Jan 1, 2019
99.65 M USD
Jan 1, 2020
195.58 M USD
Jan 1, 2021
176.20 M USD
Jan 1, 2022
206.71 M USD
Jan 1, 2023
189.66 M USD
Jan 1, 2024
154.04 M USD
Jan 1, 2025
223.01 M USD
The 10X Genomics Current Liabilities history
YEARCurrent LiabilitiesYoY
223.01 MUSD+44.77%
154.04 MUSD-18.78%
189.66 MUSD-8.25%
206.71 MUSD+17.32%
176.20 MUSD-9.91%
195.58 MUSD+96.26%
99.65 MUSD+118.88%
45.53 MUSD+33.65%
34.07 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

10X Genomics Stock analysis

What does 10X Genomics do? 10X Genomics is a US-based company specializing in the development of life science products. It was founded in 2012 by Serge Saxonov and Ben Hindson and is headquartered in Pleasanton, California. The company's business model focuses on providing technology platforms that enable researchers and scientists to analyze and understand complex biological data. It combines microfluidics, genomics, and bioinformatics. 10X Genomics is divided into different divisions, each focusing on different products and applications: Single-Cell Genomics, Long-Read Sequencing, Immune Profiling, and Spatial Transcriptomics. The company's products include the Chromium platform for cell type identification, disease research, and drug screening; Long-Read Sequencing technology for reading larger DNA fragments; tools and solutions for immune profiling and understanding the immune system; and Spatial Transcriptomics technology for studying the spatial organization of gene expression in tissues. 10X Genomics also offers other products and solutions in the field of genomic sequencing and analysis, including DNA preparation and sequencing kits, software for DNA data analysis and interpretation, and consulting and training services. The company has received various awards and recognition for its innovative approach, including the Innovation Award from The Scientist magazine and the Disruptive Technology Award from the Wall Street Journal. Overall, 10X Genomics has become a leading company in the life science industry, contributing to the advancement of scientific understanding and supporting progress in medicine and biotechnology. 10X Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 10X Genomics stock

Current Liabilities of 10X Genomics is 223.01 M USD in 2025.

Current Liabilities of 10X Genomics changed from 154.04 M USD to 223.01 M USD, representing a 44.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities 10X Genomics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's 10X Genomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — 10X Genomics

All Key Metrics — 10X Genomics